Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CTH | P32929 | 1/20 | 0.30 |
| ▸ | CBS | P35520 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21390148 | 0.77 | TSHR (0.33) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL23294625 | 0.77 | TSHR (0.33) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL21390150 | 0.77 | TSHR (0.33) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL20722025 | 0.75 | CYP11B1 (0.32) | — | |
| SCHEMBL28976351 | 0.75 | ITGB3 (0.35) | ITGB3ITGA2BPDK2TSHRCTH | |
| SCHEMBL20721981 | 0.74 | TSHR (0.35) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL25475513 | 0.74 | TSHR (0.35) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL22614110 | 0.74 | TSHR (0.35) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL21384165 | 0.72 | TSHR (0.33) | ITGB3ITGA2BTSHRCTHCBS | |
| SCHEMBL25961307 | 0.72 | TSHR (0.33) | ITGB3ITGA2BTSHRCTHCBS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. | 2022-12-29 | — | — | US | disclosed |
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ITGB3 3964/4885ITGA2B 2884/4885PDK2 2983/4885 |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ITGB3 3964/4885ITGA2B 2884/4885PDK2 2983/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | ITGB3 1906/4885ITGA2B 1835/4885PDK2 4084/4885 |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ITGB3 3964/4885ITGA2B 2884/4885PDK2 2983/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | ITGB3 3643/4885ITGA2B 2817/4885PDK2 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.